Pfizer Inc. (NYSE: PFE) will share data across its expansive infectious disease portfolio, including company-sponsored and collaborative research studies, spanning both licensed and investigational vaccines, and antibiotic and antiviral therapies at IDWeek 2022 held in Washington, D.C. October 19-23, 2022. Data from 35 abstracts involving Pfizer vaccines and anti-infective therapies will illustrate the diversity of the portfolio and the company's cutting-edge scientific approach. This will include a late-breaking presentation of the full data from its Phase 3 (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease) clinical trial, investigating its bivalent RSV A and B, stabilized RSV prefusion F subunit vaccine candidate, RSVpreF, when administered to adults 60 years of age and older. These data will also be presented on October 20, 2022, to the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP).
"The data presented at this year's IDWeek showcase the breadth of Pfizer's vaccine and therapeutic research and development portfolio and our continued commitment to working to overcome infectious diseases that still present a serious health risk," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. "We look forward to both sharing our exciting data, as well as connecting with the scientific community to determine how we can continue to work to bring transformative solutions to thwart infectious diseases."
The research to be presented includes new insights on bacterial and viral infections, including Lyme disease and C. difficile. Additionally, presentations will includePfizer's licensed vaccine, PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), and its investigational vaccine candidates RSVpreF and Group B Streptococcus, GBS6. Beyond vaccines, Pfizer is also presenting new data regarding PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), its authorized oral treatment for COVID-19.
Key Pfizer sponsored, investigator-sponsored and collaborative research oral and poster presentations leveraging the depth of Pfizer's scientific advances include:
- An oral presentation on the effect of nirmatrelvir/ritonavir versus placebo on COVID-19 related hospitalizations and other medical visits
- A poster presentation on sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo
- A poster presentation of a Phase 2 study evaluating the safety, tolerability, and immunogenicity of a booster dose of a Group B Streptococcus vaccine
Details for the Pfizer-sponsored, investigator-sponsored and collaborative research oral and poster presentations are below:
Title/Abstract Number |
Presenting Author/Type |
Date/Time (EST) |
Location |
ORAL PRESENTATIONS |
|||
786 - Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits |
Jennifer Hammond, PhD |
Oct 20 3:30 - 3:45 PM US ET |
147 AB |
91 - Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization |
Kimberly J. Center, M.D. |
Oct 20 10:30 - 10:45 AM US ET |
144 ABC |
LATE BREAKING VACCINE STUDIES |
|||
LB748 - Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults |
Edward E. Walsh, MD |
Oct 20 2:21 - 2:33 PM US ET |
209 ABC |
POSTERS - PFIZER PRESENTING |
|||
COVID-19 |
|||
1156 - Sustained Alleviation and Resolution of Targeted COVID-19 Symptoms with Nirmatrelvir/Ritonavir versus Placebo |
Jennifer Hammond, PhD |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1077 - Understanding the Psychosocial Burden Associated with Hospitalization Among Adults Diagnosed with COVID-19 in the United States |
Wajeeha Ansari, MPH |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
C. difficile |
|||
117 - Preferences for Clostridioides difficile Vaccine Attributes Among Adults in the United States |
Jeffrey T. Vietri, PhD |
Oct 20 12:15 - 1:30 PM US ET |
Virtual |
393 - Healthcare and Out-of-Pocket Costs Associated With Clostridioides difficile Infection Among US Adults 18-64 Years of Age |
Holly Yu, MSPH |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
396 - Incidence and Attributable Mortality of Clostridioides difficile Infection Among US Adults 18-64 Years of Age |
Jennifer Judy, MS, PhD |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
387 - Differences in frequency of C. difficile infection testing of inpatients with diarrhea at selected acute care hospitals in NY and GA, 2020 |
Scott Fridkin, MD |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
394 - Impact of Misdiagnosis of Clostridioides difficile Infection (CDI) by Standard-of-care Specimen Collection and Testing on Estimates of Hospitalized CDI Incidence Among Adults in Louisville, Kentucky, 2019-2020 |
Frederick Angulo, DVM PhD |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
Pneumococcal Disease |
|||
576 - Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States |
Liping Huang, MD, MA, MS |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
586 - Systematic Literature Review of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) Effectiveness Against Invasive Pneumococcal Disease in Children Globally |
Johnna Perdrizet, MPH |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
Lyme Disease |
|||
1351 - A Retrospective Database Study of Lyme Borreliosis Incidence and Distribution in Poland from 2015 to 2019 |
James Stark, Ph.D. |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1352 - Exploring spatial and temporal trends in the incidence of Lyme borreliosis in Finland using surveillance data, 2015-2020 |
James Stark, Ph.D. |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1353 - Incidence of Lyme Borreliosis in Germany: Exploring Observed Trends Over Time Using Public Surveillance Data, 2016-2020 |
James Stark, Ph.D. |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1354 - Incidence, time trends and geographic distribution of Lyme neuroborreliosis in Denmark using public surveillance data, 2015-2019 |
James Stark, Ph.D. |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1361 - Lyme Borreliosis (LB) is a Significant Disease Burden in Germany: Estimated LB Incidence after Adjusting for Under-ascertainment by Public Health Surveillance, 2021 |
Frederick Angulo, DVM PhD |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1462 - Validating a claims-based algorithm for Lyme Disease in Massachusetts |
Sarah J. Pugh, PhD, MPH |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
Antimicrobial Surveillance |
|||
659 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales Collected from Patients with Bloodstream Infections (BSI) as Part of the ATLAS (India) Surveillance Program, 2019-2020 |
Abhisek Routray, PhD |
Oct 20 12:15 - 1:30 PM US ET |
Virtual |
Other |
|||
2134 - A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6) |
Babalwa Jongihlati, MD, MBA |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
2207 - Rates of Lower Respiratory Tract Infections Among US Adults Aged ≥18 Years With and Without Chronic Medical Conditions |
Kari Yacisin, M.D. |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
2208 - Rates of Medically-Attended RSV among US Adults: A Systematic Review and Meta-Analysis |
Farid L. Khan, MPH |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
106 - High Maternal Tdap Vaccine Uptake During Early Part of Vaccination Window: Implications for Future Maternal Vaccines |
Amy W. Law, PharmD |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
POSTERS - PFIZER CO-AUTHORS |
|||
COVID-19 |
|||
1068 - Prior SARS-CoV-2 Infection And Risk of Subsequent COVID-19-Related Hospitalization: A Test Negative Design |
Khalel De Castro |
Oct 21 12:15 - 1:30 PM US ET |
Hall B + C |
1908 - Social Risk Factors for COVID-19-Related Hospitalizations in Adults |
Olivia D. Reese, BA |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1934 - Association between Receipt of COVID-19, Influenza, and Pneumococcal Vaccination |
Chris Choi, BA |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
RSV |
|||
371 - Adding sputum and saliva to nasopharyngeal swab samples for PCR detection of Respiratory Syncytial Virus in adults hospitalized with acute respiratory illness may double case detection |
Julio A. Ramirez, MD, FACP |
Oct 20 12:15 - 1:30 PM US ET |
Hall B + C |
Antimicrobial Surveillance |
|||
1717 - In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020 |
Mark Estabrook, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1719 - In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2020 |
Mark Estabrook, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1720 - In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Urinary Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2020 |
Mark Estabrook, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1673 - In vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2017-2020 |
Meredith Hackel, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1707 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected |
Mark Wise, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1708 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected |
Mark Wise, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
1709 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America, ATLAS Global Surveillance Program 2018-2020 |
Mark Wise, PhD |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
2043 - In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type |
Michael D. Huband, BS |
Oct 22 12:15 - 1:30 PM US ET |
Hall B + C |
Pfizer Conference Call
Pfizer Inc. invites Pfizer investors and the general public to view and listen to "RSV Data and COVID Vaccine Commercial Update," a webcast of a live conference call with investment analysts at 4:30 p.m. ET on October 20.
To view and listen to the webcast visit Pfizer's web site at www.pfizer.com/investors or directly at https://pfizer.rev.vbrick.com/#/events/c5b674a0-5663-4030-a863-16ecfb0a0f9b. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to pre-register in advance of the conference call.
